SAM #36C25726Q0611

Sole Source Procurement Notice for XOFIGO (Radium-223 dichloride) for VA

This notice announces the Department of Veterans Affairs' intent to award a sole source contract for XOFIGO® (Radium-223 dichloride). - Agency: Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17 - Sole source contract to Cardinal Health for XOFIGO® (Radium-223 dichloride) - Bayer Healthcare is the Original Equipment Manufacturer (OEM) - Cardinal Health is the exclusive US distributor designated by Bayer Healthcare - Quantity: 1,000 units (EA/uCi) of XOFIGO® - Statutory authority: 41 U.S.C. 3304(a)(1), FAR 6.302-1 (only one responsible source) - Firm-fixed price procurement; not open for competition unless a comparable source is identified within 7 days - Other vendors may submit capability statements or quotations to challenge the sole source determination - No other products or services are included; procurement is strictly for XOFIGO® - Place of performance/contracting office: 5441 Babcock Road, Suite 302, San Antonio, TX 78240 - Estimated contract value: $500,000 - $1,500,000 (based on typical pricing for radiopharmaceuticals)

Technical and business highlights: - XOFIGO® is a radiopharmaceutical used in cancer treatment - Only Bayer Healthcare's XOFIGO®, distributed by Cardinal Health, is acceptable for this requirement - Opportunity for other vendors is limited to demonstrating equivalent capability and distribution rights - Sole source justification is based on exclusive distribution and OEM requirements

Description

Presolicitation Notice Notice of Intent to Award a Sole Source Procurement

The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17, intends to award a firm-fixed priced contract to Cardinal Health for the procurement of the following item:

0001: XOFIGO® (Radium-223 dichloride), Unit of Issue: EA (uCi), Qty.: 1,000

The proposed sole source procurement will be made with a price agreement set by Bayer Healthcare.

Bayer Healthcare has designated Cardinal Health as their sole distributor for XOFIGO® in the United States.

This notice is not to be considered a request for quotations or proposals. No contract will be awarded based on offers received in response to this notice; however, all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. Proposals or offers received will be used to determine if a comparable source is available and more advantageous to the government. If no affirmative written response is received within 7 days from the publication of this notice, a contract or order will be issued to Cardinal Health without any further notice.

The anticipated statutory authority permitting other than full and open competition for the requirement is 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1, only one responsible source and no other supplies or services will satisfy agency requirements.

View original listing